Physician profile
Ronald D Brown
NPI 1801846779
$5,473.04
in general payments reported to CMS, 2019-2025
25 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $986 · 2021: $462 · 2022: $432 · 2023: $458 · 2024: $475 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $1,738.20 | 2019-2022 | |
| Smith+Nephew, INC. | $929.16 | 2019-2024 | Collagenase Santyl, Grafix Pl, Acticoat 4" X 4" |
| Organogenesis INC. | $528.51 | 2019-2025 | Apligraf, Puraply Wound Matrix, Puraply |
| Paratek Pharmaceuticals, INC. | $500.95 | 2019-2025 | Nuzyra |
| Next Science LLC | $318.93 | 2022-2024 | Blastx, Xperience, Surgx |
| Mimedx Group, INC. | $311.00 | 2024-2025 | |
| Osiris Therapeutics INC. | $219.71 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $172.42 | 2020 | |
| Kci USA, INC. | $155.37 | 2019-2021 | |
| Solventum Corporation | $100.54 | 2024-2025 | Activ.A.C. |
| Abbvie INC. | $85.06 | 2021-2024 | |
| Inari Medical, INC. | $77.47 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Melinta Therapeutics, LLC | $75.38 | 2019 | |
| Medline Industries Lp | $56.95 | 2019-2023 | |
| Reapplix INC. | $31.38 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apria Healthcare LLC | $27.75 | 2021 | |
| Nabriva Therapeutics, Plc | $20.45 | 2021 | |
| Hydrofera LLC | $17.19 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $17.18 | 2025 | Farxiga |
| Polymedics Innovations INC. | $17.17 | 2023 | |
| Reprise Biomedical, INC. | $17.00 | 2025 | Miro3d |
| Kerecis Limited | $17.00 | 2022 | |
| Tactile Systems Technology INC | $15.57 | 2025 | Nimbl, Flexitouch Plus |
| Convatec INC. | $11.69 | 2019 | |
| Merck Sharp & Dohme LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.